Over the past two decades, major improvements in the treatment of chronic inflammatory diseases have been achieved. The introduction of TNF biologics such as infliximab has significantly improved disease control and enabled long-term remission in many patients.
Therapeutic Drug Monitoring (TDM) of biotherapies is a well-recognized tool that supports evidence-based treatment decisions and optimizes biologic therapy usage. However, until recently, the benefits of TDM for infliximab were not available at the true point of care.
Current testing limitations often delay dose adjustments by weeks after trough level testing. Procise IFX overcomes these barriers by enabling immediate dose adjustment decisions at the time of infusion.
Procise IFX allows immediate decisions on drug dose adjustments at the time of infusion in less than 5 minutes using finger-prick blood, and can be performed by virtually any level laboratory technician.
| Parameter | Details |
|---|---|
| Sample Types | Finger prick whole blood, venous blood, or serum |
| Reportable Range | 1.7 µg/mL – 77.2 µg/mL |
| Time to Results | Less than 5 minutes |
| Stability | 2 years at room temperature |
| Validated for | Infliximab (Remicade®, Remsima®, Inflectra®, Flixabi® and Renflexis®) |
Calibrated against WHO standard.